January 21, 2026

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Growth Code: 4593)

Healios Initiates Production of Culture Supernatant at In-house Cell Processing Facility

HEALIOS K.K. ("Healios") is advancing research and development aimed at utilizing the technology we possess for producing regenerative medicine products and the culture supernatant generated during their production process. To prepare for the anticipated full-scale production of culture supernatant, we have been developing a Cell Processing Center (CPC) within the Business Support Center for Biomedical Research Activities (BMA) in Kobe. We are pleased to announce that this facility has now commenced full operations.

Culture supernatant holds promise for utilization across various fields, including as a material for pharmaceuticals and cosmetics. Healios is advancing discussions with multiple reputable business partners regarding research and sales aimed at utilizing culture supernatant. We will leverage this CPC for these applications.

Overview of the CPC

(1) Address:
1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe City, Hyogo Prefecture. Within the Business Support Center for Biomedical Research Activities (BMA)
(2) Total floor area: Approximately 80m²
(3) Purpose of use: Production of Culture Supernatant



Future Outlook
This matter will have no impact on the Company's consolidated results for the fiscal year ending December 2026. We will promptly announce any matters that should be disclosed in the future.

About Healios:
HEALIOS K.K. is Japan's leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. It aims to offer new therapies for patients suffering from diseases without effective treatment options. Healios is a pioneer in the development of regenerative medicines in Japan and owns proprietary, global platforms utilizing both somatic stem cells and iPS cells.

In the somatic stem cell field, Healios is developing invimestrocel (HLCM051), a proprietary cell product comprised of multipotent adult progenitor cells ("MAPCs") derived from the bone marrow of healthy adult donors. Invimestrocel has been shown to exhibit powerful anti-inflammatory and immunomodulatory properties with applicability in a range of disease states, has been tested in hundreds of patients in late stage clinical trials, is manufactured consistently at scale in 3D bioreactors, and has demonstrated both safety and suggested efficacy in hundreds of patients across multiple indications. Healios is seeking to advance invimestrocel on a global basis for ARDS, ischemic stroke, and trauma.

In the iPSC regenerative medicine field, Healios is developing HLCN061, a next generation NK cell treatment for solid tumors that has been functionally enhanced through gene-editing. These cells have demonstrated robust anti-tumor efficacy in animal models, benefit from a scalable 3D bioreactor manufacturing process, and are currently being prepared for initial human testing in collaboration with Akatsuki Therapeutics. The company has also established a proprietary, gene-edited "universal donor" induced pluripotent stem cell line to develop next generation regenerative treatments in immuno-oncology, ophthalmology, liver diseases, and other areas of severe unmet medical need.

Healios was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593). https://www.healios.co.jp/en

Contact:
IR & PR Division
HEALIOS K.K.
E-mail: ir@healios.jp